| Pharmacologic
classification: Delavirdine (de-la-VIR-deen) is a synthetic non-nucleoside
reverse transcriptase inhibitor (NNRTI).
Dosage:
varies based on the patient but is usually 400 mg (four 100-mg tablets
or two 200-mg tablets) three times daily.
Indications
for use: helps to keep HIV from reproducing and is used in combination
with at least two other antivirals to treat HIV infection.
Pharmacodynamics:
binds to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent
DNA polymerase activities.
Pharmacokinetics:Absorption:
peak concentration occurs within one hour. Food reduces absorption by 20%
but delavirdine may be administered with or without food. Patients with
achlorhydria should take Rescriptor with an acidic beverage such as orange
or cranberry juice to increase absorption. Advise patients taking both
Rescriptor and antacids to take them at least one hour apart so the absorption
of delavirdine will not be reduced.
Distribution:
98% is bound to plasma proteins. Metabolism: extensively metabolized in
the liver, mainly by cytochrome P450 3A (CYP3A) but may also be metabolized
by CYP2D6, to various inactive products.
Excretion:
elimination primarily in urine and stool. |
